YSB’s B2B Pharma Platform: Sexier Than the SOEs, But Stodgier Than B2Cs
The drug distributor for pharmacies and community-level medical institutions has filed for a Hong Kong listing, boasting strong revenue growth but also massive losses Key Takeaways: YSB has filed for…
RELATED ARTICLES
-
Slowing revenue growth hurts online drug platform YSB
9885.HK
-
Profits recover at Alibaba Health but prognosis unclear
0241.HK
- Margins ring alarm bells as 160 Health readies IPO
-
Rebounding Perfect Medical finds beauty safe haven in Hong Kong
1830.HK
- Medical imaging group Rimag sets growth focus with IPO
-
Ping An Health pins recovery hopes on new leadership
1833.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
Discover hidden China stock gems in our weekly newsletter